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Monocytes play multiple roles in the immune system, and are active in both acute
and chronic diseases. Patients exposed to bacterial infections depend onmonocytes
in defense reactions, but excessive immune reactions may also cause morbidity
through systemic inflammatory responses. Few studies have addressed the
importance of proteoglycans, and in particular, the hematopoietic serglycin, in
such monocyte immune reactions. Adherent primary monocytes were cultured in
absence and presence of LPS. Media were analyzed by ELISA for detection of
serglycin. Lysed cell fractions were used to determine the mRNA level of serglycin.
Monocytes were also cultured on chamber slides to investigate if serglycin could be
detected intracellularly by immunocytochemistry. Monocytes secreted serglycin,
and LPS-stimulation increased the secretion. Secretion of inflammatory cytokines
increased to a larger extent than serglycin. mRNA levels of serglycin were also
increased, suggesting both increased expression and secretion. Immunocytochem-
istry revealed the presence of serglycin in intracellular vesicles, many destined for
secretion. Serglycin containing vesicles increased in number and size when the cells
were exposed to LPS. Intracellular vesicle localization and secretion of the
proteoglycan serglycin is shown for the first time in primary human monocytes.
Monocyte activation by LPS increased the expression and secretion of serglycin,
suggesting roles for serglycin in inflammatory processes.
Introduction
Non-resolving inflammation is a driving force in several acute
and chronic diseases, and postulated to be one of the greatest
contributors to the medical burden in developed countries.
Exaggerated or insufficient inflammatory responses from
the innate immune system can lead to organ dysfunction and
shock [1]. Excessive inflammatory responses also cause
morbidity and mortality in chronic diseases such as diabetes
mellitus, atherosclerosis, and autoimmune diseases [2–4].
Monocytes are potent innate immune cells, representing
2–10% of total leukocyte counts in circulating blood. They
are important in immediate responses to infections, and
the non-classical and the intermediate subpopulations
are increased in numbers in several acute and chronic
diseases [5]. Pattern recognition receptors on the immune
cells recognize pathogen-associated molecular patterns or
damage-associated molecular patterns. Lipopolysaccharide
(LPS) is a classic pathogen-associated molecular pattern
which is found in the outer cell membrane of gram-negative
bacteria. Monocytes are activated when LPS bind to Toll-like
receptor 4 [6]. This activates a cascade of intracellular
signaling pathways, culminating in increased production of
cytokines such as tumor necrosis factor (TNF)a, interleukin
(IL)-1a, IL-1b, IL-6, CXCL8, and transforming growth
factor (TGF)-b [2, 6].
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Human blood monocytes are divided into three subsets; the
classical strongly CD14-positive (CD14þþCD16) monocyte,
the intermediate CD14- and CD16-positive monocyte
(CD14þþCD16þ), and the non-classical monocyte, which is
strongly CD16-positive (CD14þCD16þþ). The intermediate
and the non-classical monocyte together are often referred to as
CD16þ (CD16-positive) monocytes [7]. By serum deprivation
for 90min, human peripheral bloodmononuclear cells (PBMC)
will adhere in vitro. Such adherentmonocytes are dominated by
CD16-positive cells [8]. Levels of these cells are expanded in
septic patients, in patients suffering from chronic kidney disease,
during inflammatory diseases, and in patients with localized
infections [9–12]. These cells are potent producers of TNFa and
IL-1b in response to LPS [8, 13].
Monocytes also secrete proteoglycans (PGs) in response to
LPS-stimulation [14]. PG secretion in human monocytes is
increased with various immunological stimuli, such as
LPS [14]. In early studies the secreted PGs were identified
based on the nature of their glycosaminoglycan chains, not the
protein core. Primary human monocytes express almost
exclusively PGs with chondroitin 4-sulfate chains, whereas
differentiated macrophages express both chondroitin 4-sulfate
and chondroitin 4,6-disulfate (Chondroitin sulfate E) [15, 14,
16]. Serglycin has been identified as the major PG in human
monocyte cell lines [16, 17], but has not been studied to any
great extent in primary human monocytes. The major part is
constitutively secreted under in vitro conditions and has an
approximate molecular weight over 220 kDa [18]. Cell
fractions of primary human monocytes have previously been
shown to contain more free chondroitin sulfate chains than
intact PGs [16]. In murine macrophages serglycin is also the
major secreted PG [16, 19], increased after LPS stimulation and
important for the secretion of TNFa. Also, in endothelial cells
LPS increase the secretion of serglycin [20]. Serglycin has earlier
been shown to co-localize with inflammatory mediators in
secretory vesicles in endothelial cells, cytotoxic T-cells andmast
cells, suggesting a role for serglycin in storage and secretion of
inflammatory mediators [21, 22]. CD16-positive cells have
been shown tobepotent producers of classic pro-inflammatory
mediators [10, 13, 23]. The aim of this study was to investigate
serglycin expression, localization, and secretion in cultured
primary humanCD16-positivemonocytes [8], before and after
LPS stimulation. Results presented suggest that serglycin
expression and secretion is part of the inflammatory response




Peripheral blood mononuclear cells (PBMC) were obtained
from Buffy coats suspended in endotoxin-free PBS (Sigma),
using Lymphoprep density gradient (Axis-Shield Poc AS)
according to the manufacturers instruction. The PBMC
fraction was suspended in RPMI1640 with L-glutamine
(Gibco) and antibiotics (penicillin and streptomycin (Sig-
ma)) and 5mMof glucose (Sigma)without serum, and plated
onto plastic chamber slides (Nalge Nunc International).
Monocytes were allowed to adhere for 90min at 378C/5%
CO2, before washing three times with RPMI1640 to remove
non-adherent cells. The adherent cells were then cultured in
RPMI1640, with L-glutamine/antibiotics, 10% heat inacti-
vated fetal calf serum (Sigma), and 5mM of glucose, and in
presence or absence of 1mg/ml LPS derived from Escherichia
coli (O26:B26 from Sigma–Aldrich (Sigma)). The cultures
were incubated for 3, 6 and 24 h, respectively. Adherent cells
obtained by this method have previously been shown to be
highly enriched in CD16-positive monocytes, as 60% of the
cells in such cultures areCD16high.Only 20%of the cellswere
shown to be of the main blood monocyte population
(CD14high)—also referred to as classical monocytes [8].
Serglycin ELISA
Serglycin released from the adherent monocytes was measured in
culture supernatants using an enzyme-linked immunosorbent
assay (ELISA) according toNiemann et al. [24], using theGenesis
software, on Thermo Electron Corporation Multiskan EX.
Quantitative real-time PCR
RNA from primary monocytes was isolated using the E.Z.N.
A total RNA kit 1 (Omega Bio-Tek). RNasin1 Plus RNase
Inhibitor (Promega) was added to the isolated RNA, and the
RNA was stored at 808C for later reverse transcription to
cDNA. From each sample, 90 ng of total RNA was reverse
transcribed using High Capacity RNA-to-cDNA Kit (Ap-
plied Biosystems). Quantitative real-time (qRT) PCR was
performed with TaqMan Gene Expression Master Mix
(Applied Biosystems), cDNA and dH2O up to 20ml. Specific
mRNA levels were determined by qRT-PCR performed on
ABI PRISM 7900 HT Sequence detector system (Applied
Biosystems), using TaqMan gene expression assays (cata-
logue no. Hs01004159_m1 for serglycin) and the house-
keeping genes b-actin and RPL30 (catalogue no.
Hs99999903_m1 and Hs00265497_m1, respectively; Ap-
plied Biosystems). All samples were run in triplicates, and
the housekeeping genes and target genes were run on the
same plate. The relative mRNA level for each transcript was
calculated by the DDcycle threshold (Ct) method [25].
Immunocytochemistry
Adherent monocytes grown on chamber slides were washed
three times in PBS, fixed in 4% paraformaldehyde for
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10min, and washed in PBS for 10min. Both primary and
secondary antibodies were diluted in 1.25% BSA containing
0.2% saponin and spun at 13000 rpm for 5–10min at 48C
before use. The cells were incubated with primary antibody
affinity purified rabbit anti-human serglycin (1mg/ml,
kindly provided by N. Borregaard) or the affinity purified
concentration matched irrelevant control for serglycin
(rabbit anti-Hemocyanin (KLH), Sigma–Aldrich), over-
night at 48C in a dark humidity chamber. Some wells were
only incubated with dilution buffer without primary
antibodies, to test for specificity of the secondary antibody.
The slides were then washed twice for 5min in PBS and
incubated with a secondary antibody, Alexa Fluor 488
conjugated goat anti-rabbit IgG (1:600, Invitrogen), for
90min in a dark humidity chamber at room temperature.
Finally, the slides were washed in PBS for 10min, washed in
MQ-H2O, air dried, and mounted using SlowFade Gold
antifade reagent with DAPI (Invitrogen). Cells were
examined with an Olympus FluoView FV1000 confocal
microscope (Olympus Corporation, Tokyo, Japan) and a
PlanApo 60x/1.40 oil objective. All images were obtained by
sequential scanning under the same setting using FV10-ASW
3.1 software. Image processing was performed with Photo-
shop CS4 software (Adobe).
Statistical analysis
Data in Figures 1 and 2 were analyzed with GraphPad Prism
5.03. Differences between the groups were analyzed using the
non-parametrical Wilcoxon matched pairs test. Differences
of P 0.05 were considered significant. Differences between
the groups in Figure 3 were analyzed using the non-
parametric Friedman test for repeated measures, with
multiple corrections performed with the Dunns post-hoc
test with columns to be compared selected on the basis of
experimental design.
Results and Discussion
LPS increased the secretion and expression of
serglycin in monocytes
To investigate the possible implications of serglycin in
monocytes exposed to LPS stimulation, supernatants were
subjected to ELISA using an antibody against human
serglycin. The results obtained show that serglycin is a
secretory product of LPS-activated human primary mono-
cytes. The PG serglycin has previously been shown to be a
secretory product of the monocyte-like cell lines U937 [16]
and THP-1 cells [17]. In this study serglycin secretion in
primary humanmonocytes is demonstrated for the first time.
In monocytes incubated with LPS, secretion of serglycin
was significantly increased 3.3 times after 3 h, as can be seen
Figure 1. Secretion of serglycin in LPS-activated human adherent
monocyte cultures is increased. Cultures of adherent human monocytes
from seven separate donorswere exposed to either LPS (1mg/ml) or saline
for 3 (A), 6 (B), or (C) 24 h, at 378C with 5% CO2. Secreted serglycin
found in the media was quantified by ELISA. *P 0.05.
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in Figure 1A. After 6 h the increase was 3.0 times, whereas the
stimulatory effects observed after 24 h incubation were
weaker (approximately 1.5 times)—but still significant. In
addition, the increased secretion of serglycin is supported by
a corresponding increased mRNA expression (Fig. 2),
evident by the doubling of mRNA levels after 3 and 6 h
and approximately fourfold increase after 24 h compared to
controls. In unstimulated cells the increase in serglycin
secretion is time dependent and lower than in LPS
stimulated cells. The effect of LPS on serglycin is rapid
and secretion is sustained at this high level through the entire
incubation period. It is worth noting that the high serglycin
secretion is followed by a higher level of serglycin mRNA in
stimulated compared to control cells after 24 h, suggesting
feedback mechanisms in the LPS treated cells.
In control cells there is a constitutive and low secretion
of serglycin, while the secretion of chemokines and
cytokines is at a very low level and not increasing with
time. The effect of LPS on the secretion of chemokines and
cytokines was determined by a multiplex antibody bead
kit. LPS was a potent inducer of secretion of TNF-a, IL-1a
and b, CXCL8, CCL2, 3 and 4 and IL-6, as can be seen in
Figure 3. Stimulatory effects were obvious after 3 h and
increased in a time dependent manner. These results,
demonstrating increased secretion of chemokines and
cytokines, were further supported by the large increase also
seen in mRNA levels, determined by qRT-PCR (data not
shown) for all these cytokines and chemokines, thereby
confirming effects of LPS on both expression and
secretion. Accordingly, the secretion pattern for serglycin
differed from those of the chemokines and cytokines
investigated, suggesting an early role of serglycin in
inflammatory reactions. From these results we conclude
that serglycin may be regarded as a part of the secretory
repertoire of human monocytes, and thereby the innate
immune defense. The increase in secretion after LPS
stimulation suggests that serglycin has functions related to
inflammatory reactions, possibly involving serglycin in
secretion and transport of inflammatory mediators.
Early studies on PG secretion in monocyte cell lines did
not allow for identification of serglycin, but was based on
radiolabeling of GAG-chains with 35S-sulfate. Activation
with LPS increased 35S-PG secretion twofold, whereas
interferon-g treatment attenuated the secretion [14], dem-
onstrating that PG secretion in human monocytes is subject
to different types of regulation depending on type of stimuli.
The increased secretion of inflammatory mediators from
LPS-activatedmonocytes after stimulation coincides with an
increase in serglycin secretion. This may reflect the
importance of serglycin as a secretory vehicle—and thereby
dampening or promoting effects on inflammation. This
suggests that serglycin may be an important factor in
monocyte defense mechanisms. We demonstrate that
Figure 2. Serglycin mRNA expression in LPS-activated human primary
monocytes is increased. Adherent monocytes from 4–6 healthy persons
were exposed to LPS (1mg/ml) or saline for 3 (A), 6 (B), and 24 (C) hours,
at 378C with 5% CO2. RNA was isolated and assayed for serglycin by
quantitative RT-PCR. Data are shown as mean fold change from
monocytes exposed to saline. *P 0.05.
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Figure 3. LPS-induced cytokine and chemokine release. Human adherent monocytes from seven separate donors were treated with saline or LPS (1mg/
ml). After 3, 6, and 24h of incubation at 378Cwith 5%CO2,mediawere harvested and analyzed for TNFa (A), IL-1a (D), IL-1b (C), IL-6 (B), CCL2 (F), CCL3
(G), CCL4 (H), and CXCL8 (E) with amultiplex antibody bead kit. Levels of CCL3 from LPS-stimulatedmonocytes at 24 hwere above range inmost donors
at this time-point (hence, data not shown). Each LPS stimulation point is compared to its own control. *P 0.05, **P 0.005, ***P 0.001.
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immediate secretion more than expression of serglycin,
which is a later effect, is altered by an inflammatory stimulus.
In a study by Zernichow et al, TNFa secretion from
macrophages derived from serglycin/ mice increased
when stimulated with LPS. The increased level of TNFa was
due to increased secretion, not synthesis [19]. In the same
study, secretion of MMP-9, IL-1a, and CCL3 was not
altered [19]. A study performed on LPS-activated endothe-
lial cells showed that secretion of CXCL8 was unaltered by
loss of serglycin [20]. It is therefore possible that serglycin
Figure 4. Immunostaining reveals intracellular vesicles containing serglycin in adherent human monocytes. The panels show adherent monocytes
incubated in the presence (right) or absence (left) of LPS (1mg/ml), for 3, 6, and 24h. The cells were fixed, and stained for serglycin (green). Positive DAPI
staining (blue) show the nucleus. Bar¼ 50mM.
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selectively interact with some chemokines more than others
and that such interactions may differ between cell types.
Serglycin is present in intracellular vesicles in
monocytes
Serglycin secretion has not previously been studied in
primary human monocytes in any great detail. To further
investigate serglycin secretion in LPS activated monocytes,
cells were fixed and subjected to immunocytochemistry.
From Figure 4, it can be demonstrated that monocytes
contained both large and small serglycin-positive vesicles at
all three time points (3 h, 16 h, and 24 h—both in the
presence and the absence of LPS. After 3 h of LPS
stimulation, no significant differences in the distribution
or sizes of the vesicles were observed. After 6 h however, LPS-
stimulated cells showed stronger serglycin staining with an
increased number of larger vesicles, compared to the
unstimulated cells. In control cells, the vesicles were
concentrated more closely to the plasma membrane. In
LPS-stimulated monocytes serglycin containing vesicles
tended to be more evenly distributed throughout the entire
cytoplasm. After 24 h, however, the size and intracellular
localization of serglycin positive vesicles were similar in
control and LPS stimulated cells. The data presented on
serglycin secretion using ELISA suggest that levels secreted
after 24 h are still higher than in control cells, but at the same
levels as after 3 h of stimulation. The lack of difference in
serglycin staining after 24 h can, however, indicate that
secretion reaches a peak after LPS stimulation and that the
cells thereafter return to a state of basal level secretion, as in
controls.
The immunocytochemical demonstration of serglycin in
secretory vesicles, increasing in number and size after LPS
stimulation, further supports the hypothesis that serglycin
has functions related to the inflammatory response. One
such function could be to regulate secretion of cytokines and
chemokines, as has been demonstrated in other serglycin
expressing hematopoietic cells [21] and endothelial
cells [22].
The extracellular role(s) of serglycin
Another intriguing aspect of serglycin secretion is the
possibility that it may have functions in the extracellular
environment of activated monocytes following secretion. It
has been demonstrated that perforin and granzyme B
delivered from cytotoxic T-cells to target cells are found in
complex with serglycin, suggesting functions for serglycin-
related targeted extracellular transport of inflammatory
mediators [26]. Moreover, in serglycin overexpressing cells it
has been demonstrated that secretion of active proteases
depend on the expression of serglycin [27]. In monocytes,
secreted 35S-PGs rich in serglycin was purified and added
back to fresh cultures of monocytes. The 35S-PGs were not
degraded to any great extent and remained in the culture
medium. No cellular uptake or degradation could be
demonstrated [28]. We have also demonstrated that CCL3
binds to serglycin [29] and that deletion of the GAG binding
domain in CCL3 reduced its chemoattractant activity [30].
These data and the data presented here suggest that serglycin
secreted from human monocytes has extracellular and
inflammatory functions. An increased secretion of serglycin
from human monocytes after LPS exposure suggests that
serglycin can be involved in secretion, protection, and
delivery of such partner molecules during inflammatory
reactions.
Future aspects
It has been suggested that serglycin may participate in the
formation of chemotactic gradients of secretory products
from different types of hematopoietic cells. Serglycin has also
been detected on cells surfaces [31, 32], including breast
cancer cells, suggesting interactions with cell surface
components [33]. These are fascinating new aspect of PG
biology [34, 35] that deserves to be addressed in future
studies. Moreover, serglycin may be secreted directly to the
extracellular environment. It cannot be excluded that
serglycin is retained within secretory vesicles or exosomes.
Preliminary studies in our laboratory show the presence of
serglycin in microparticles (Reine, unpublished data).
Possible interactions between intracellular serglycin and
storage and secretion of inflammatory mediators should be
studied in order to determine if serglycin has mainly
proinflammatory or antiinflammatory abilities—or both. In
order to explore the role of serglycin in immunological
reactions, serglycin/mice represent a useful in vivomodel.
Furthermore, secreted vesicles containing serglycin should
be analyzed for possible complexes between inflammatory
mediators and serglycin.
Concluding Remarks
The data presented show that primary CD16-positive
monocytes from healthy donors secrete serglycin as part
of their inflammatory response to LPS. We also demonstrate
for the first time that serglycin is found in secretory vesicles
in primary monocytes. Together, these results suggest a role
for serglycin in the innate immune defense system.
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